Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NRX PharmaceuticalsNRXP 29 Receivables Turnover is 6.25 as of Mar. 2026. GuruFocus rates NRXP with a GF Score™ of 29/100. The stock has 3 warning signs investors should review. Among 842 Biotechnology companies, NRX Pharmaceuticals ranks better than 82.42% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. NRX Pharmaceuticals's Revenue for the
three
months ended in Mar. 2026 was $1.07 Mil. NRX Pharmaceuticals's average Accounts Receivable for the
three
months ended in Mar. 2026 was $0.17 Mil.
Hence, NRX Pharmaceuticals's Receivables Turnover for the
three
months ended in Mar. 2026 was 6.25.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
NRX Pharmaceuticals Receivables Turnover Related Terms
NRX Pharmaceuticals Receivables Turnover Historical Data
* Premium members only.
The historical data trend for NRX Pharmaceuticals's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NRXP vs NKTX, YDES, TNXP: Receivables Turnover Comparison
For the Biotechnology subindustry, NRX Pharmaceuticals's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NRX Pharmaceuticals Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, NRX Pharmaceuticals's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where NRX Pharmaceuticals's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NRX Pharmaceuticals (NRXP) has a Receivables Turnover of 6.25 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on NRX Pharmaceuticals and its competitors. According to the industry distribution chart, NRX Pharmaceuticals ranks #148 out of 842 companies in the Biotechnology industry, placing it in the top 17.6%.
Is NRX Pharmaceuticals' Receivables Turnover too high?
NRX Pharmaceuticals' current Receivables Turnover is 6.25. The Biotechnology industry median Receivables Turnover is 5.30. NRX Pharmaceuticals' value of 6.25 is 18% above this industry median. Based on the distribution chart, NRX Pharmaceuticals ranks #148 out of 842 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, NRX Pharmaceuticals has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does NRX Pharmaceuticals' Receivables Turnover compare to NKTX and YDES?
According to the Biotechnology industry distribution chart, NRX Pharmaceuticals ranks #148 out of 842 companies for Receivables Turnover. This places NRX Pharmaceuticals in the top 18% of its industry — outperforming the majority of peers. The industry median Receivables Turnover is 5.30. NRX Pharmaceuticals' value of 6.25 is 18% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.30, based on 842 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NRX Pharmaceuticals's current Receivables Turnover of 6.25 is 18% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on NRX Pharmaceuticals and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NRX Pharmaceuticals's current Receivables Turnover is 6.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NRX Pharmaceuticals stock overvalued right now?
NRX Pharmaceuticals (NRXP) has a current Receivables Turnover of 6.25. The current Receivables Turnover is 6.25 and 18% above the Biotechnology industry median of 5.30. NRX Pharmaceuticals' overall GF Score™ is 29/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For NRX Pharmaceuticals (NRXP), the current Receivables Turnover is 6.25 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company is developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
29GF Score
Get the complete analysis for NRXP
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NRXP has been successfully added to your 
